Investigational drug · Phase 2
STC-15
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Solid Tumor, Sarcoma, Leiomyosarcoma.
Phase 2Last checked: Nov 19, 2026Latest source record: Oct 22, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
3
Any phase or sponsor naming "STC-15"
First trial start
2025
May 5, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "STC-15", any sponsor or status.
Conditions studied
As listed on its trial records.
- Solid Tumor
- Sarcoma
- Leiomyosarcoma
- Dedifferentiated Liposarcoma
Largest trials
Live from ClinicalTrials.gov: studies naming "STC-15" as an intervention, largest first.
STORM Therapeutics LTDIndustry
NCT06975293 · 107 participants (planned) · Start May 5, 2025 · Primary completion Dec 29, 2027
Drug: STC-15 in combination with toripalimab; STC-15 monotherapy · For: Solid Tumor; Sarcoma; Leiomyosarcoma and 1 more
Sites: San Francisco, California; Miami, Florida; Boston, Massachusetts · 14 sites in all
STORM Therapeutics LTDIndustry
NCT05584111 · 42 participants · Start Nov 15, 2022 · Primary completion Aug 30, 2024
Drug: STC-15 · For: Advanced Cancer; Advanced Solid Tumor; Cancer
Sites: Scottsdale, Arizona; Houston, Texas; San Antonio, Texas
STORM Therapeutics LTDIndustry
NCT07906093
Drug: STC-15 · For: Cancer
Newest research
PubMed records naming it or its code names, newest first.
- The role of RNA modifications in cancer translational control.
Joy M, Cleynen A, Shirokikh NE · RNA Biol 2026
- Small Molecule Inhibitors Targeting METTL3 in Cancer: Preclinical and Clinical Advances, Combination Strategies.
Ren Q, Sun H, Ji L, et al. · Eur J Pharmacol 2026
- Targeting m6A Reader Phase Separation in Synaptic Plasticity: A Hypothesis-Generating Framework for Epitranscriptomic Drug Discovery.
Rastmanesh R · Epigenomes 2026
- R-loops: Biological functions, regulatory mechanisms, and therapeutic implications in brain diseases-A review.
Sun R, Duan X, Wang X, et al. · Mol Cell Probes 2026
- Mutant KRAS-m6A Epitranscriptome Axis Promotes Colorectal Cancer and is a Therapeutic Target.
Chen D, Huang P, Tao R, et al. · Adv Sci (Weinh) 2026
- Epitranscriptomic regulation in the progression of cancer and platinum resistance.
Harvanik P, Hudáková T, emeláková M, et al. · Adv Med Sci 2026
Also in development for Solid Tumor
- BMS-986507BL-B01D1, Iza-brenPhase 351 trials
Sichuan Baili Pharmaceutical Co., Ltd. · Non-small Cell Lung Cancer, Solid Tumor, Urothelial Carcinoma
- SintilimabIBI308Phase 321 trials
Innovent Biologics (Suzhou) Co. Ltd. · Hepatocellular Carcinoma, Solid Tumor, HCC - Hepatocellular Carcinoma
- IfebemtinibIN10018, BI853520Phase 311 trials
InxMed (Shanghai) Co., Ltd. · Solid Tumor, NSCLC, Solid Tumor Cancer
- JAB-21822Glecirasib Citrate, KRAS G12C inhibitorPhase 310 trials
Allist Pharmaceuticals, Inc. · Non-small Cell Lung Cancer, KRAS P.G12C, Solid Tumor
- FavezelimabMK-4280, MK-4820APhase 39 trials
Merck & Co. · Melanoma, Carcinoma, Renal Cell, Solid Tumors
- PD-1 monoclonal antibodyPhase 39 trials
Sichuan Baili Pharmaceutical Co., Ltd. · Nasopharyngeal Carcinoma (NPC), Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma
- PD-1 inhibitorPhase 38 trials
BioAtla, Inc. · Advanced Solid Tumors, Gastric or Gastroesophageal Junction Adenocarcinoma, NSCLC (Advanced Non-small Cell Lung Cancer)
- RC148Phase 38 trials
RemeGen Co., Ltd. · Previously Untreated Locally Advanced (IIIB/IIIC) or Metastatic (IV) e Nsq NSCLC Without Actionable Genomic Alterations, Solid Tumor, Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.